Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimab + apatinib + albumin paclitaxel for second-line advanced neuroendocrine tumors
ChiCTR2600128061Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, Rivoceranib and nab-paclitaxel in apudoma (NET), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Started Jul 2026; status: recruiting.
02
Drugs
adebrelimabRivoceranibnab-paclitaxel
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on ChiCTR2600128061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128061.